Joo-Pin Foo1, Stergios A Polyzos, Athanasios D Anastasilakis, Sharon Chou, Christos S Mantzoros. 1. Division of Endocrinology, Diabetes, and Metabolism (J.-P.F., S.A.P., S.C., C.S.M.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; Department of Endocrinology (A.D.A.), 424 General Military Hospital, 54006 Thessaloniki, Greece; and Section of Endocrinology (C.S.M.), Boston Veterans Affairs Healthcare System, Harvard Medical School, Boston, Massachusetts 02130.
Abstract
CONTEXT: Recombinant leptin (metreleptin) treatment restores bone mineral density in women with hypothalamic amenorrhea (HA), a condition characterized by hypoleptinemia, which has adverse impact on bone health. OBJECTIVE: The objective of the study was to investigate how metreleptin exerts its positive effect on bone metabolism in humans. DESIGN: This was a randomized, double-blinded, placebo-controlled study. SETTING: The study was conducted at Beth Israel Deaconess Medical Center (Boston, Massachusetts). PATIENTS AND INTERVENTIONS: Women (n = 18) with HA and hypoleptinemia for at least 6 months were randomized to receive either metreleptin or placebo for 36 weeks. Serum samples were obtained at baseline and 12, 24, and 36 weeks of treatment. MAIN OUTCOME MEASURES: Circulating levels of leptin, intact PTH (iPTH), receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), sclerostin, dickkopf-1, and fibroblast growth factor-23. RESULTS:Metreleptin administration significantly increased leptin levels throughout the treatment period (P = .001). iPTH decreased over the 36 weeks of treatment (P = .01). There was a trend toward a decrease in serum RANKL and increase in serum OPG in the metreleptin-treated group. The RANKL to OPG ratio was significantly decreased within the metreleptin (P = .04) but not the placebo group. Metreleptin had no effect on serum sclerostin, dickkopf-1, and fibroblast growth factor-23. CONCLUSIONS:Metreleptin treatment over 36 weeks decreases iPTH and RANKL to OPG ratio levels in hypoleptinemic women with HA.
RCT Entities:
CONTEXT: Recombinant leptin (metreleptin) treatment restores bone mineral density in women with hypothalamic amenorrhea (HA), a condition characterized by hypoleptinemia, which has adverse impact on bone health. OBJECTIVE: The objective of the study was to investigate how metreleptin exerts its positive effect on bone metabolism in humans. DESIGN: This was a randomized, double-blinded, placebo-controlled study. SETTING: The study was conducted at Beth Israel Deaconess Medical Center (Boston, Massachusetts). PATIENTS AND INTERVENTIONS:Women (n = 18) with HA and hypoleptinemia for at least 6 months were randomized to receive either metreleptin or placebo for 36 weeks. Serum samples were obtained at baseline and 12, 24, and 36 weeks of treatment. MAIN OUTCOME MEASURES: Circulating levels of leptin, intact PTH (iPTH), receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), sclerostin, dickkopf-1, and fibroblast growth factor-23. RESULTS: Metreleptin administration significantly increased leptin levels throughout the treatment period (P = .001). iPTH decreased over the 36 weeks of treatment (P = .01). There was a trend toward a decrease in serum RANKL and increase in serum OPG in the metreleptin-treated group. The RANKL to OPG ratio was significantly decreased within the metreleptin (P = .04) but not the placebo group. Metreleptin had no effect on serum sclerostin, dickkopf-1, and fibroblast growth factor-23. CONCLUSIONS: Metreleptin treatment over 36 weeks decreases iPTH and RANKL to OPG ratio levels in hypoleptinemic women with HA.
Authors: Jean L Chan; Joseph E Mietus; Patricia M Raciti; Ary L Goldberger; Christos S Mantzoros Journal: Clin Endocrinol (Oxf) Date: 2007-01 Impact factor: 3.478
Authors: Elizabeth Sienkiewicz; Faidon Magkos; Konstantinos N Aronis; Mary Brinkoetter; John P Chamberland; Sharon Chou; Kalliopi M Arampatzi; Chuanyun Gao; Anastasia Koniaris; Christos S Mantzoros Journal: Metabolism Date: 2011-07-07 Impact factor: 8.694
Authors: Sharon H Chou; John P Chamberland; Xiaowen Liu; Giuseppe Matarese; Chuanyun Gao; Rianna Stefanakis; Mary T Brinkoetter; Huizhi Gong; Kalliopi Arampatzi; Christos S Mantzoros Journal: Proc Natl Acad Sci U S A Date: 2011-04-04 Impact factor: 11.205
Authors: K K Miller; M S Parulekar; E Schoenfeld; E Anderson; J Hubbard; A Klibanski; S K Grinspoon Journal: J Clin Endocrinol Metab Date: 1998-07 Impact factor: 5.958
Authors: M T Muñoz-Calvo; V Barrios; M T García de Alvaro; M Lefort; C Méndez-Dávila; J Argente; C de la Piedra Journal: Scand J Clin Lab Invest Date: 2007 Impact factor: 1.713
Authors: Sara A Armaiz-Flores; Nichole R Kelly; Ovidiu A Galescu; Andrew P Demidowich; Anne M Altschul; Sheila M Brady; Van S Hubbard; Courtney K Pickworth; Marian Tanofsky-Kraff; Lauren B Shomaker; James C Reynolds; Jack A Yanovski Journal: Horm Res Paediatr Date: 2017-03-30 Impact factor: 2.852